Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reimbursement Rejection On Cost Grounds For “Highly Effective” Trodelvy In England

Country Out Of Sync With Other Project Orbis Markets On Gilead Product

Executive Summary

In a draft decision NICE, the health technology appraisal body for England and Wales, has declined to recommend Gilead’s Trodelvy for triple negative breast cancer patients.

You may also be interested in...

Dutch Minister Demands ‘Socially Acceptable’ Price For Gilead’s Trodelvy

Gilead’s breast cancer drug Trodelvy is too expensive for the benefits it offers and will not be reimbursed in the Netherlands unless the company drops its price, said the Dutch health minister.

The Evolution Of Drug Regulation In Post-Brexit Britain

Regulatory reliance is playing an increasingly important role in gaining marketing authorization in the UK following Brexit. Meanwhile, the country’s unique Innovative Licensing and Access Pathway is attracting growing levels of interest, not just from companies but from regulators and health technology appraisal bodies across the world.

New Pricing Deals Pave Way For Piqray & Trodelvy Reimbursement In England

Health technology assessment body NICE has reversed its previous rejections of Novartis’s Piqray and Gilead’s Trodelvy, both for treating advanced breast cancer. Meanwhile, there are calls to speed up reimbursement decisions for breast cancer drugs.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts